What public health recommendations changed for the 2025-2026 flu season based on 2025 vaccine performance?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Health authorities kept the core public-health message for 2025–26: everyone aged ≥6 months should get an updated flu vaccine, and the 2025–26 U.S. vaccines were reformulated as trivalent to match circulating A(H1N1), A(H3N2) and B/Victoria viruses (FDA/CDC decisions March–June 2025) [1] [2]. ACIP and FDA also changed programmatic details — single‑dose thimerosal‑free preference for most groups, expanded age approvals for products (Flublok to ≥9 years) and home/self administration approval for FluMist — which affected ordering, supply and administration guidance for the season [3] [2].
1. Why recommendations stayed the same on “get your shot” despite mixed 2024–25 VE data
Public health agencies continued to recommend universal vaccination because surveillance and interim VE studies showed vaccines provided meaningful protection against severe outcomes and were the best tool to reduce hospitalizations and deaths, not because they always fully prevented infection (CDC interim VE reports and VE networks) [4] [5]. Independent reviews also signaled ongoing benefit of respiratory‑virus immunization programs for the 2025–26 season and urged using updated vaccines despite year‑to‑year variation in effectiveness (NEJM review) [6].
2. Vaccine composition and why 2025–26 vaccines are trivalent
FDA and WHO processes led to specific strain selections for 2025–26 and resulted in U.S. vaccines being formulated as trivalent (A(H1N1)pdm09, A(H3N2), and B/Victoria lineage) with slight differences by production method (egg‑based vs. cell/recombinant) — decisions published after reviewing U.S. and global surveillance and mid‑season VE data (FDA composition recommendation; WHO composition document; CDC season page) [1] [7] [2].
3. Programmatic changes that altered how vaccines are delivered
ACIP and FDA changes for 2025–26 were operational: FluMist (LAIV3) was approved for self‑ or caregiver administration for certain ages, Flublok (recombinant vaccine) expanded its age indication to ≥9 years, and ACIP recommended single‑dose, thimerosal‑free formulations for children, pregnant women and all adults — prompting jurisdictions and providers to remove multi‑dose vials from many public programs and update ordering guidance [3] [8].
4. How 2024–25 performance shaped strain selection and surveillance emphasis
Mid‑season and network VE analyses for 2024–25 identified clade diversification (for example H1N1 clades 5a.2a and 5a.2a.1) and uneven protection by subtype; those data were explicitly used in the spring 2025 composition reviews that set 2025–26 vaccine strains (MMWR interim VE analysis; FDA composition recommendation) [5] [1]. Agencies emphasized enhanced surveillance to catch emerging mismatches (CDC and FDA meeting materials reflected this focus) [1] [2].
5. Conflicting signals and how authorities weighed them
Some single‑site studies questioned effectiveness in particular populations (for example a Cleveland Clinic preprint reporting no effectiveness in working‑age employees), but national surveillance and multi‑network VE analyses and the Southern Hemisphere interim data suggested vaccines reduced outpatient visits and hospitalizations substantially in 2025 surveillance snapshots — public agencies prioritized the broader, multi‑network evidence when setting recommendations (medRxiv preprint; CDC Southern Hemisphere interim MMWR) [9] [10]. Professional bodies (AAP) nonetheless reiterated routine annual vaccination for children, reflecting consensus among pediatric experts despite isolated negative or null studies [11] [12].
6. Practical implications for clinicians, programs and the public
Clinicians were told to offer any age‑appropriate licensed product as soon as available, with program managers adjusting stock and procurement away from multi‑dose vials for public programs and emphasizing vaccination in September–October for most people (NC division memo; CDC guidance pages) [8] [2]. FDA and ACIP label and administration changes broadened options — e.g., home administration of FluMist and a younger eligible cohort for Flublok — which may improve access and uptake if logistics follow [3] [2].
7. Limits and open questions in the reporting
Available sources document the composition changes, ACIP/FDA policy shifts and surveillance rationale, but they do not provide a single numeric “VE by age across all sites” that would reconcile conflicting single‑center studies with multi‑network results; isolated preprints reported negative point estimates while pooled public‑health analyses reported protection against severe outcomes [9] [5] [10]. Jurisdictions also acted differently on product availability (e.g., VFC program decisions), reflecting operational tradeoffs not fully standardized in federal documents [8].
Bottom line: policy for 2025–26 emphasized updated, trivalent vaccination for everyone ≥6 months plus programmatic changes (product approvals, single‑dose preference) to improve safety, access and logistics; the guidance reflects broad surveillance and multi‑network VE evidence that vaccines reduce severe outcomes even when protection against infection varies year to year [2] [1] [5] [3].